20:41 , Oct 10, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Rett syndrome Mouse studies suggest positive allosteric modulators (PAMs) of mGluR7 could help treat Rett syndrome. In a mouse model of the disease, an mGluR7 PAM tool compound increased memory, novel object recognition and...
20:51 , Mar 23, 2017 |  BC Week In Review  |  Clinical News

AEVI-001: Ph II/III SAGA data

Top-line data from the double-blind, U.S. Phase II/III SAGA trial in 96 evaluable ADHD patients ages 12-17 with genetic disorders impacting mGluRs showed that twice-daily oral AEVI-001 missed the primary endpoint of reducing ADHD-RS total...
22:39 , Mar 20, 2017 |  BC Extra  |  Clinical News

Aevi plummets after ADHD candidate fails in Phase II/III

Aevi Genomic Medicine Inc. (NASDAQ:GNMX) shed $3.23 (59%) to $2.21 on Monday after it said AEVI-001 missed the primary endpoint in the Phase II/III SAGA study to treat ADHD in adolescent patients with metabotropic glutamate...
21:45 , Feb 1, 2017 |  BC Week In Review  |  Clinical News

AEVI-001: Ph I/II started

Aevi began an open-label, U.S. Phase I/II trial evaluating 50, 100, 200 and 400 mg oral AEVI-001 twice daily over 5 weeks in about 12 patients ages 12-17 with a 22q11.2 deletion and diagnosed with...
07:00 , Jun 27, 2016 |  BC Week In Review  |  Clinical News

NFC-1: Phase II/III started

Medgenics began the double-blind, placebo-controlled, U.S. Phase II/III SAGA trial to evaluate 100, 200 and 400 mg oral NFC-1 twice daily for 6 weeks in 90 patients ages 12-17. In 1H17, Medgenics plans to start...
07:00 , Oct 5, 2015 |  BC Week In Review  |  Company News

neuroFix Therapeutics, Medgenics deal

Medgenics acquired neuroFix for $2 million in cash and more than $481 million in potential milestones. neuroFix is eligible to receive $6 million in cash and stock upon the earlier of the completion of an...
07:00 , Oct 24, 2013 |  BC Innovations  |  Strategy

Synaptic synopsis

The early promise that neurotransmitter research would unlock the door for neurological diseases has devolved into sagging interest from several pharmas following repeated failures in clinical trials. Now, genetic findings are pointing to new targets...
08:00 , Jan 5, 2012 |  BC Innovations  |  Targets & Mechanisms

Fine-tuning mGluRs

Studies by two American teams have converged on a family of metabotropic glutamate receptors as players in attention deficit hyperactivity disorder and autism spectrum disorder. 1,2 The findings build an argument for agonizing the receptors...
08:00 , Jan 5, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Attention deficit hyperactivity disorder (ADHD) Metabotropic glutamate receptor subtype 5 (mGluR5; GRM5); mGluR7 (GRM7); mGluR8 (GRM8) A genomewide association study suggests agonizing mGluR5, mGluR7 or...